3 results
Approved WMORecruiting
To evaluate the long-term safety of zanubrutinib in patients with B-cell cancers who participated in a BeiGene parent study for zanubrutinib
Approved WMORecruiting
We aim to introduce 166Ho radioembolization combined with systemic chemotherapy and investigate its safety and feasibility.
Approved WMORecruiting
All primary and secondary objectives will compare zanubrutinib (also known as BGB-3111) plus rituximab followed by zanubrutinib monotherapy versus bendamustine plus rituximab followed by observation only.Primary:• To compare efficacy, as measured by…